Previous Close | 1.8700 |
Open | 1.8400 |
Bid | 1.9250 x 0 |
Ask | 1.9400 x 0 |
Day's Range | 1.8400 - 1.9900 |
52 Week Range | 1.3050 - 5.0000 |
Volume | |
Avg. Volume | 19,229 |
Market Cap | 140.244M |
Beta (5Y Monthly) | 1.36 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3300 |
Earnings Date | May 23, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for DIGN.ST
Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp Cooling System in Switzerland and Liechtenstein. OncoMedical specializes in medical technology products in the areas of oncology, pain therapy and palliative care. OncoMedical will purchase at least eight DigniCap Delta devices and the corresponding patient consumables in 2024 to launch the product which minimizes hair loss from chemotherapy, with the first order for three devices s
Scalp cooling innovator Dignitana AB announces today a sales and marketing partnership with InfuSystem Holdings, Inc., a leading health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers in the United States.
Dignitana announces that the Palmetto GBA Medicare Administrative Contractor (MAC) has issued a Local Coverage Determination (LCD) to provide coverage guidance for Scalp Cooling for the Prevention of Chemotherapy-Induced Alopecia. According to the final LCD guidance from Palmetto GBA, "the use of a scalp hypothermia device that has been approved by the United States (U.S.) Food and Drug Administration (FDA) for the prevention of chemotherapy-induced alopecia (CIA) shall be considered reasonable